Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Increased to Overweight at JPMorgan Chase & Co.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Marketbeat Ratings reports. The firm presently has a $12.00 price objective on the stock, up from their previous price objective of $9.00. JPMorgan […]
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Marketbeat Ratings reports. The firm presently has a $12.00 price objective on the stock, up from their previous price objective of $9.00. JPMorgan […]
